Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

PURPOSE: The safety, tolerability, and pharmacokinetic (PK) interactions of MK-0646 in combination with cetuximab and irinotecan were investigated in Japanese patients with advanced colorectal cancer. METHODS: Twenty patients were treated in the following study arms in combination with cetuximab and...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Doi, Toshihiko, Muro, Kei, Yoshino, Takayuki, Fuse, Nozomu, Ura, Takashi, Takahari, Daisuke, Feng, Hwa-ping, Shimamoto, Takashi, Noguchi, Kazuo, Ohtsu, Atsushi
التنسيق: Artigo
اللغة:Inglês
منشور في: Springer Berlin Heidelberg 2013
الموضوعات:
Original Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3753462/
https://ncbi.nlm.nih.gov/pubmed/23921573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2240-8
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة